2-Year Treasury Yield Rises to 4.885% This Quarter -- Data Talk
Dow Jones2026/09/30 19:25The 2-year yield rose 0.747 percentage point to 4.885% this quarter, the price closing at 99 24/32.
--Largest one-quarter yield gain since June 2023
--Yield is up for three consecutive quarters
--Yield is up 1.417 percentage points over the last three quarters
--Largest three-quarter yield gain since the fourth quarter 2022
--This Month it is up 0.537 percentage point
--Largest one-month yield gain since Feb. 2023
--Yield is up for seven consecutive months
--Yield is up 1.508 percentage points over the last seven months
--Largest seven-month yield gain since Feb. 2023
--Longest streak of rising yields since April 2022 when the yield rose for nine straight months
--Yield is up eight of the past nine months
--Today it is down 0.002 percentage point and the price is unchanged
--Yield is down for two consecutive trading days
--Yield is down 0.037 percentage point over the last two trading days
--Largest two-day yield decline since Thursday, Sept. 3, 2026
--Yield is down three of the past four trading days
--Today's yield is the fifth highest this year
--Yield is off 0.037 percentage point from its 52-week high of 4.922% hit Monday, Sept. 28, 2026
--Yield is up 1.508 percentage points from its 52-week low of 3.377% hit Friday, Feb. 27, 2026
--Yield is up 1.343 percentage points from 52 weeks ago
--Year-to-date the yield is up 1.417 percentage points
Data based on 3 p.m. ET values
Source: Tradeweb FTSE U.S. Treasury Closing Prices
(END) Dow Jones Newswires
September 30, 2026 15:25 ET (19:25 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results
Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.
Kroger (KR.US) faces the largest layoffs in 143 years: cutting one-third of positions, more than 3,000 employees to be let go
Kroger has laid off 3,000 employees, accounting for more than one-third of its total workforce, marking the largest layoff in its 143-year history. The resources saved will be redirected towards price reductions and frontline operations.
RBA Minutes: Case for rates to act promptly to keep inflation expectations anchored
Crypto prices
More
